Satavaptan

Satavaptan

Systematic (IUPAC) name
N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide
Identifiers
CAS Number	185913-78-4
ATC code	none
PubChem	CID 9810773
ChemSpider	32699105
UNII	AJS8S3P31H
Chemical data
Formula	C33H45N3O8S
Molar mass	643.789 g/mol
SMILES CCOc1cc2c(cc1)N(C(=O)[C@@]23CC[C@@H](CC3)OCCN4CCOCC4)S(=O)(=O)c5c(cc(cc5)C(=O)NC(C)(C)C)OC CCOc1cc2c(cc1)N(C(=O)[C@@]23CC[C@@H](CC3)OCCN4CCOCC4)S(=O)(=O)c5c(cc(cc5)C(=O)NC(C)(C)C)OC
InChI InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+ Key:QKXJWFOKVQWEDZ-VCCCEUOBSA-N
(what is this?)  (verify)

Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonist^[1] undergoing research for the treatment of hyponatremia. It is also being studied for the treatment of ascites.^[2]

It was developed by Sanofi-Aventis. As of 2008, it is under regulatory review in the European Union.

References

1. Soupart A, Gross P, Legros JJ, et al. (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clin J Am Soc Nephrol 1 (6): 1154–1160. doi:10.2215/CJN.00160106. PMID 17699341.
2. Ginès P, Wong F, Watson H, Milutinovic S, Ruiz Del Arbol L, Olteanu D (February 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial". Hepatology 48 (1): 204–213. doi:10.1002/hep.22293. PMID 18508290.